Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7454-7461

  Morris, Michael J ^a,b   Divgi, Chaitanya R ^a,b   Pandit Taskar, Neeta ^a   Batraki, Maria ^a   Warren, Nyasha ^a   Nacca, Angelo ^a   Smith Jones, Peter ^a   Schwartz, Lawrence ^a   Kelly, W Kevin ^a,b   Slovin, Susan ^a,b   Solit, David ^a,b   Halpern, Jennifer ^a   Delacruz, Anthony ^a   Curley, Tracy ^a   Finn, Ronald ^a   O'Donoghue, Joseph A ^a   Livingston, Philip ^a,b   Larson, Steven ^a,b   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERIC ACID; GLYCOPROTEIN; IMMUNOGLOBULIN G1; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CASTRATION; CHILL; CLINICAL ARTICLE; COUGHING; DESQUAMATION; DIARRHEA; DOSE CALCULATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; DYSURIA; EDEMA; EPITHELIUM CELL; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; IMMUNOGENICITY; MYALGIA; NAUSEA; NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RASH; RIGOR; SIDE EFFECT; THORAX PAIN; THROMBOSIS; TISSUE DISTRIBUTION; URINARY FREQUENCY;

AGED; ANEMIA; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CELL LINE, TUMOR; CELL SURVIVAL; COMPLEMENT ACTIVATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THROMBOSIS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 27144544111     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0826     Document Type: Article

References (23)

1. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-30.
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
3. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
4. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
5. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
6. Wright GL, Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
7. Chang SS, Reuter VE, Heston DWD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
8. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7.
9. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-43.
10. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-21.
11. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
12. 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;22:2522-31.
13. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991;9:478-90.
14. Press OW, Eary JR, Applebaum FR, et al. Radiolabled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
15. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
16. 177Lu) in advanced prostate cancer (PCa) [abstract 18]. Proc Am Soc Clin Oncol 2002;21:5a.
17. Bander NH, Nanus D, Bremer S, et al. Phase I clinical trial targeting a monoclonal antibody (mAb) the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer [abstr 1872]. Proc Am Soc Clin Oncol 2000;19:477a.
18. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted α therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 2002;5:36-46.
19. McDevitt MR, Barendswaard E, Ma D, et al. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
20. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998;58:2844-9.
21. Nagy E, Berczi I, Sehon AH, Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 1991;34:63-9.
22. Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 1987;47:2771-6.
23. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14.